A pivotal trial of PLX-R18 in acute radiation syndrome (ARS)

Trial Profile

A pivotal trial of PLX-R18 in acute radiation syndrome (ARS)

Planning
Phase of Trial: Phase III

Latest Information Update: 10 May 2018

At a glance

  • Drugs PLX R18 (Primary)
  • Indications Acute radiation syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Pluristem Therapeutics
  • Most Recent Events

    • 10 May 2018 According to Pluristem Therapeutics media release, the company anticipates FDA clearance for this trial by the end of 2018.
    • 07 Feb 2018 According to Pluristem Therapeutics media release, company is collaborating with the U.S. Department of Defense (DOD) Armed Forces Radiobiology Research Institute (AFRRI). This study is conducted and funded by AFRRI and data from this study is expected in 2018.
    • 25 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top